

PCV vaccines indicator

Financing & funding

Estimated financial cost of materials per vaccine dose (syringes, needles, safety box) (in USD)

Cost of syringes: UNICEF procurement US\$ 0.028 to US\$ 0.065 depending on supplier and product / PAHO RF procurement US\$ 0.028 to US\$ 0.048 depending on supplier and product. [1](#), [2](#), [3](#)

Cost of safety boxes: UNICEF procurement, a box of 25 safety boxes (each with a 5-liter capacity) is about US\$ 20.26, resulting in approximately US\$ 0.81 per safety box. Each 5-liter safety box can hold around 100 syringes, leading to a disposal cost of approximately US\$ 0.008 per syringe. [3](#), [4](#)

Estimated vaccine financial cost per dose (in USD)

As of June 2026, the **UNICEF** price per dose for 2026 for countries accessing **Gavi** prices, ranges between US\$ 2.00 for PCV10, 5 doses presentation (Serum Institute of India) and US\$ 3.30 for PCV13 single dose presentation (Pfizer). Prices are expected to change in 2027 starting from US\$ 1.55 for PCV10, 5 doses presentation (Serum Institute of India). For Middle Income Countries (MICs), UNICEF prices per dose for 2026 range between US\$ 4.00 and US\$ 18.05 depending on

country income level, supplier, valency and presentation. Prices for humanitarian use and countries in fragile states range between US\$ 2.00 and US\$ 7.00 depending on country, supplier, valency and presentation. ⁵

UNICEF prices are subject to change. Access to the most up to date price can be found at the following link: [Pneumococcal Conjugate Vaccine \(PCV\) price data | UNICEF Supply Division](#)(1) Users are encouraged to confirm those prices by contacting UNICEF Supply Division.

As per the 2025 **PAHO** price list, the price per dose for the Revolving Fund for Access to Vaccines ranges between US\$ 2.00-2.90 for PCV10, US\$ 13.50 for PCV13, and US\$ 20.00 for PCV20. ⁶

As per the April 2026 **US CDC** pricelist, the cost per dose of pediatric PCV vaccine in the United States ranges between US\$184.18 and US\$200.13. ⁷

As per the 2024 **WHO/UNICEF Joint Reporting Form** reported data, the price per dose for **self-procuring MICs** is on average US\$ 19.20 (range US\$ 3.03-59.32 depending on country income level, supplier and valency). ⁸

Estimated financial cost per person vaccinated (in USD)

Cost of delivery (health facility based): ranges between US\$ 0.06 and US\$ 3.96 per dose. ^{9, 10, 11, 12, 13, 14}

Cost-effectiveness ratio

The cost-effectiveness of PCV use depends on many factors, including the burden of disease, vaccine effectiveness, indirect effects, vaccination coverage, vaccine price, delivery costs and schedule. ^{15, 16} An analysis of data from 22 studies in low- and middle-income countries showed that vaccination with PCV10-GSK and PCV13-PFZ using a 3p+0 or 2p+1 schedule is cost-effective from the perspectives of both the healthcare system and society. ¹⁶ The cost-effectiveness according to product choice will depend on country characteristics, including local serotype distribution and coverage rates achieved with different schedules. ^{15, 16, 17, 18}

Is there a Gavi programme to support the introduction of this vaccine?

If a Gavi programme is available, what support is available to countries?

Gavi supports PCV introduction since 2009 with use of Pneumococcal Advance Market Commitment up to 2020. Contracts with manufacturers continue through 2029. Gavi provides support for routine introduction and catch-up introduction funding PCVs and injection supplies and vaccine introduction grants. ¹⁹

Sources

1.

UNICEF (2025). Auto-disable (AD) syringe price data. UNICEF Supply Division. Updated January 2025. Available at: <https://www.unicef.org/supply/documents/auto-disable-ad-syringe-price-data> (accessed 5 August 2025)

2.

Pan American Health Organization (PAHO) (2024). Revolving Fund syringe prices 2024. PAHO/WHO Revolving Fund for Access to Vaccines. Last update April 2024. Available at: <https://www.paho.org/en/documents/revolving-fund-syringe-prices-2024> (accessed 5 August 2025)

3.

UNICEF (2025). Syringe and safety box bundles price data. UNICEF Supply Division. Updated early 2025. Available at: <https://www.unicef.org/supply/documents/syringe-and-safety-box-bundles-price-data> (accessed 5 August 2025)

4.

Safety box price data. UNICEF Supply Division. Updated January 2025. Available at: <https://www.unicef.org/supply/documents/safety-boxes-price-data> (accessed 5 August 2025)

5.

UNICEF (2026). Pneumococcal conjugate vaccine (PCV) price data. United Nations Children's Fund. Available at: <https://www.unicef.org/supply/documents/pneumococcal-conjugate-vaccine-pcv-price-data> (accessed 16 June 2026).

6.

Pan American Health Organization (PAHO) (2025). Vaccine prices 2025. Pan American Health Organization. Available at: <https://www.paho.org/sites/default/files/2025-07/prices-vac-2025-eng-2-july-2025-v3.pdf> (accessed 16 June 2026).

7.

Centers for Disease Control and Prevention (CDC) (2026). Current CDC vaccine price list. U.S. Department of Health and Human Services. Available at: <https://www.cdc.gov/vaccines-for-children/media/pdfs/2026/03/Pediatric-VFC-Vaccine-Price-List-04-01-26-508.pdf> (accessed 16 June 2026).

8.

World Health Organization (2025). 2025 MI4A public vaccine purchase dataset. World Health Organization. Available at: <https://www.who.int/teams/immunization-vaccines-and-biologicals/vaccine-access/mi4a/mi4a-vaccine-purchase-data> (accessed 16 June 2026).

9.

AMP (2014). Costing and financing analyses of routine immunization and new vaccine introduction in Benin: Final report. Agence de Médecine Préventive. Available at https://immunizationeconomics.org/wp-content/uploads/2024/01/FINALREPORT_BENIN.pdf (accessed 5 Aug 2025)

10.

Guthrie T, Zikusooka C, Kwesiga B, Abewe C, Lagony S et al. (2014). Costing and financing analyses of routine immunization in Uganda. Health Economics and HIV and AIDS Research Division (HEARD), University of KwaZulu-Natal.

11.

Bem J and Stewart E (2015). Vaccine costing analysis: Preliminary results. Presentation at the Pharmaceutical Fund and Supply Agency, Addis Ababa, Ethiopia, September 2015.

12.

Ngabo F, Levin A, Wang SA, Gatera M, Rugambwa C et al. (2015). A cost comparison of introducing and delivering pneumococcal, rotavirus and human papillomavirus vaccines in Rwanda. *Vaccine*, 33(51), pp.7357–7363. <https://doi.org/10.1016/j.vaccine.2015.10.022>

13.

Dorji K, Phuntsho S, Pempa, Kumluang S, Khuntha S et al. (2018). Towards the introduction of pneumococcal conjugate vaccines in Bhutan: a cost-utility analysis to determine the optimal policy option. *Vaccine*, 36(13), pp.1757–1765. <https://doi.org/10.1016/j.vaccine.2018.02.048>

14.

ThinkWell (2024). Immunization delivery cost catalogue (IDCC). Available at: <https://immunizationeconomics.org/recent-activity/2024/6/11/immunization-delivery-cost-catalogue/> (accessed 5 August 2025).

15.

Chaiyakunapruk N, Somkruea R, Hutubessy R, Henao AM, Hombach J, Melegaro A et al. Cost effectiveness of pediatric pneumococcal conjugate vaccines: a comparative assessment of decision-making tools. *BMC Med*. 2011;9:53. doi: 10.1186/1741-7015-9-53.

16.

Saokaew S, Rayanakorn A, Wu DB, Chaiyakunapruk N. Cost Effectiveness of Pneumococcal Vaccination in Children in Low- and Middle-Income Countries: A Systematic Review. *Pharmacoeconomics*. 2016;34:1211-25. doi: 10.1007/s40273-016-0439-3.

17.

Krishnamoorthy Y, Elias SK, Nair NP, Sakthivel M, Sarveswaran G, Chinnakali P. Impact and cost effectiveness of pneumococcal conjugate vaccine in India. *Vaccine*. 2019;37:623-30. doi: 10.1016/j.vaccine.2018.12.004.

18.

Dilokthornsakul P, Kengkla K, Saokaew S, Permsuwan U, Techasaensiri C, Chotpitayasunondh T et al. An updated cost-effectiveness analysis of pneumococcal conjugate vaccine among children in Thailand. *Vaccine*. 2019;37:4551-60. doi: 10.1016/j.vaccine.2019.06.015.

19.

Gavi, the Vaccine Alliance (2022). Vaccine Funding Guidelines. Gavi, the Vaccine Alliance.
Available at:
https://www.gavi.org/sites/default/files/document/2022/Vaccine_FundingGuidelines_0.pdf
(accessed 5 August 2025).